(Source: Otsuka Pharmaceutical Co Ltd) Otsuka Pharmaceutical Co., Ltd. March 1, 2013 FDA Approves Once-Monthly ABILIFY MAINTENA™ (Aripiprazole) For Extended-Release Injectable Suspension for the Treatment of Schizophrenia Approval provides patients with schizophrenia the ability to access the efficacy and safety profile of oral aripiprazole in a once-monthly formulation. Relapse prevention is an important consideration in the treatment of patients with schizophrenia; ABILIFY MAINTENA met the Phase 3 clinical trial primary endpoint of significantly delaying time to relapse. ABILIFY MAINTENA will be the first commercialized product from the global alliance between Otsuka and Lundbeck focused...
↧